These are reviewed studies whose abstracts concern Endometrial Carcinosarcoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Endometrial Carcinosarcoma. Most are early lab, animal, or small human studies, and findings often conflict.
5 studies3 human⚠ Conflicting evidenceMechanism (3)Trial (1)
Tracking 5 published studies of Endometrial Carcinosarcoma: 3 in humans, 2 reviews/other.
Reported direction across studies: 2 positive, 2 mixed, 1 inconclusive.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether anything works for Endometrial Carcinosarcoma.
Human · observationalMixed resultsLimited evidenceTier 3 · early humann = 97
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Oct 2025 · multicenter retrospective study
uterine carcinosarcomaendometrial carcinosarcomaendometrial neoplasms
This multicenter retrospective study looked at 97 people with very early uterine carcinosarcoma that had not invaded the muscle layer of the uterus. The researchers compared outcomes by where the tumor was found and by whether patients received chemotherapy. Recurrence was common, mostly at distant sites, and the study did not find statistically significant survival differences with chemotherapy.
Reported effects: 5-year recurrence-free survival 63.5% [53.4–75.4], n=97 · overall survival 72% [62.6–82.9], n=97
Key findings
- 29 of 97 patients (29.9%) had a recurrence, mostly with a distant pattern of relapse.
- The 5-year recurrence-free survival was 63.5% and overall survival was 72.0%.
- No significant differences were observed in recurrence-free survival and overall survival based on tumor status.
- The difference in recurrence-free survival and overall survival was not statistically significant based on receipt of chemotherapy.
Limitations: Retrospective observational design; Rare disease with small sample size; Non-randomized treatment selection; Follow-up for survival analysis was limited to 5 years; Potential confounding by indication; No chemotherapy regimen, dose, or timing details provided in the abstract.
This study evaluates outcomes in a rare endometrial cancer subtype and compares adjuvant chemotherapy versus no chemotherapy after surgery.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical
Medicina (Kaunas, Lithuania) · Jun 2025 · review
endometrial carcinosarcomaendometrial cancercarcinosarcoma of the endometrium
This is a narrative review of endometrial carcinosarcoma (ECS), a rare, aggressive biphasic endometrial cancer. The authors summarize epidemiology, pathology including that ECS arises from epithelial components undergoing epithelial-to-mesenchymal transition, prognosis, molecular characteristics, and current and novel therapeutic approaches, noting a poor prognosis and limited high-quality trial evidence.
Reported effects: proportion_diagnosed_early 50% · proportion_with_metastatic_lymph_nodes 33% · +1 more
Key findings
- ECS is a rare, aggressive biphasic metaplastic carcinoma with a monoclonal origin composed of epithelial and mesenchymal components.
- The tumor originates from epithelial components that undergo epithelial-to-mesenchymal transition.
- Approximately half of patients are diagnosed at early stage and half at advanced stage.
- More than one-third of women present with metastatic lymph nodes and approximately 10% have distant metastases.
- ECS has the worst prognosis among endometrial cancers compared with other high-grade endometrial carcinomas.
- Surgical resection with adjuvant therapy remains the standard of care in most cases.
- Rarity of ECS limits prospective clinical trials and the development of specific management guidelines.
- The review discusses molecular characteristics and new treatment regimens for primary (early and advanced) and recurrent ECS.
Limitations: This article is a review and presents no new primary data.; The rarity of ECS limits the ability to conduct prospective clinical trials and to establish optimal treatment regimens (stated in abstract).; No specific treatment guidelines exist for ECS, reflecting limited high-quality evidence (stated in abstract)..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Meta-analysisTrialReported positiveModerate evidenceTier 4 · clinicaln = 2456
Cancer treatment reviews · Apr 2024 · meta-analysis of randomized controlled trials (first-line ICI + platinum-based chemotherapy vs chemotherapy alone)
advanced endometrial cancerrecurrent endometrial cancerendometrial carcinosarcoma
This meta-analysis pooled five randomized trials (2456 patients) comparing addition of anti-PD-1 or anti-PD-L1 agents to standard platinum-based chemotherapy versus chemotherapy alone as first-line treatment for advanced or recurrent endometrial cancer. Adding immune checkpoint inhibitors improved progression-free survival overall and especially in tumors with deficient mismatch repair (dMMR); in mismatch repair–proficient (pMMR) tumors a statistically significant PFS benefit was reported only with anti-PD-1 agents, not anti-PD-L1 agents. The analysis reports PFS outcomes; the impact on overall survival remains to be clarified.
Reported effects: included patients 2456, n=2456 · pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 · +5 more
Studied with: carboplatin-paclitaxel chemotherapy.
Key findings
- Five randomized trials comprising 2456 patients (1308 received ICIs + chemotherapy and 1148 chemotherapy alone) were included.
- Addition of ICIs to chemotherapy improved PFS in the overall population (pooled HR, 0.63; 95% CI, 0.52–0.76; P < .001).
- In the dMMR subgroup the pooled PFS benefit was larger (pooled HR, 0.34; 95% CI, 0.27–0.44; P < .001).
- In dMMR tumors benefit was seen with both PD-L1 and PD-1 inhibitors (pooled HRs 0.39, 95% CI 0.28–0.55 and 0.34, 95% CI 0.27–0.44, respectively; both P < .001).
- In pMMR patients a statistically significant PFS benefit was observed only with anti-PD-1 agents (anti-PD-1: HR 0.64, 95% CI 0.46–0.90, P = .010) but not with anti-PD-L1 agents (anti-PD-L1: HR 0.87, 95% CI 0.73–1.03, P = .104).
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human · observationalMechanismReported positiveModerate evidenceTier 3 · early humann = 216
Gynecologic oncology · Jul 2023 · Retrospective cohort of patients with endometrial or ovarian carcinosarcomas who underwent clinical tumor-normal sequencing and consented to germline assessment
endometrial carcinosarcomaovarian carcinosarcomagynecologic carcinosarcoma
The authors analyzed tumor-normal sequencing data from 216 patients with endometrial or ovarian carcinosarcoma to assess germline pathogenic variants (gPVs) and whether they show biallelic loss in tumors. They found gPVs in 29 patients (13%), many of which—particularly in homologous recombination and Lynch-mismatch repair genes—showed biallelic inactivation, suggesting these germline variants likely drive some gynecologic carcinosarcomas.
Reported effects: total_patients 216 · endometrial_percentage 77%, n=216 · +13 more
Key findings
- Of 216 patients, 167 (77%) had endometrial carcinosarcoma and 49 (23%) had ovarian carcinosarcoma.
- Overall, 33 gPVs were observed in 29 patients (13%); 20 gPVs (61%) had biallelic loss in tumors.
- The rate of high-penetrance gPVs overall was 7% (16 of 216); 88% of high-penetrance gPVs had biallelic loss.
- Endometrial cohort: 22 gPVs in 19 (11%) of 167 patients; 12 gPVs (55%) had biallelic loss, including 8 (89%) of 9 high-penetrance gPVs with biallelic loss.
- Ovarian cohort: 11 gPVs in 10 (20%) of 49 patients; 8 gPVs (73%) had biallelic loss, and all evaluable high-penetrance gPVs (n = 6) had biallelic loss.
- All gPVs in homologous recombination (BRCA1, BRCA2, RAD51C) and Lynch syndrome (MSH2, MSH6) genes had biallelic loss in tumors (n = 15).
Limitations: Retrospective, observational design with potential selection bias (patients underwent clinical sequencing and consented to germline testing).; Modest overall sample size and relatively small ovarian carcinosarcoma subgroup (n = 49).; Biallelic inactivation inferred from genomic analyses (loss of heterozygosity/somatic alterations) without functional validation experiments.; No clinical outcome or treatment-response data reported to link gPVs/biallelic loss to prognosis or therapeutic benefit..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismMixed resultsLimited evidenceTier 4 · clinical
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Feb 2023
This review summarizes current knowledge on endometrial carcinosarcoma, an aggressive high-grade endometrial carcinoma with sarcomatous trans-differentiation that is often diagnosed at an advanced stage. It describes common molecular features (frequent p53 abnormalities; variable POLE/MSI-H) and current management: multimodal therapy with optimal surgery plus chemotherapy and radiotherapy, carboplatin/paclitaxel as first-line systemic therapy for recurrent/metastatic disease, and regulatory approvals for pembrolizumab plus lenvatinib in endometrial cancer generally. The authors note that carcinosarcoma patients were excluded from many immunotherapy trials and that emerging molecular insights may enable more personalized treatments in the future.
Reported effects: proportion_in_endometrioid_components 25% · proportion_in_non-endometrioid_components 3%
Studied with: carboplatin/paclitaxel doublet, pembrolizumab + lenvatinib, concomitant or sequential chemotherapy and radiotherapy, surgery plus chemotherapy and radiotherapy (multimodal).
Key findings
- Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation.
- Clinical presentation and diagnostic work-up are similar to endometrioid endometrial cancer, but carcinosarcoma is more frequently diagnosed at an advanced stage.
- Endometrial carcinosarcoma encompasses different histological subtypes depending on the carcinomatous and sarcomatous elements.
- The majority of endometrial carcinosarcomas are characterized by p53 abnormalities.
- The proportion of POLE and microsatellite instability-high (MSI-H) is related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.
- Non-metastatic disease management is multimodal with optimal surgery followed by concomitant or sequential chemotherapy and radiotherapy, even for early stages.
- Palliative chemotherapy is recommended for metastatic or recurrent disease, with carboplatin/paclitaxel doublet as the first-line regimen.
- Patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or combinations, although pembrolizumab and lenvatinib have FDA and EMA approvals in endometrial cancer after progression on chemotherapy (and single-agent immunotherapy in MSI-H cancers).
- Emerging molecular knowledge is opening promising therapeutic options for more personalized treatment.
Limitations: This article is a narrative review rather than primary clinical trial data.; Endometrial carcinosarcoma is a rare and heterogeneous disease, limiting generalizable high-quality evidence.; Patients with carcinosarcoma were excluded from most immunotherapy studies, resulting in limited direct trial evidence for these agents in this histotype.; The abstract does not present new quantitative clinical trial outcomes specific to carcinosarcoma..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed